GlassScriptPhysician profile
Oren Y Zebaida
NPI 1114911732
$4,533.89
in general payments reported to CMS, 2019-2025
32 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $276 · 2021: $811 · 2022: $535 · 2023: $771 · 2024: $625 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $862.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $580.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $543.14 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $350.34 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $292.47 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $281.84 | 2019-2025 | |
| Amarin Pharma, INC. | $257.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.48 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.90 | 2019-2024 | Airsupra, Breztri |
| Dexcom, INC. | $98.62 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $98.14 | 2019-2021 | |
| Abbott Laboratories | $91.99 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.72 | 2019-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $76.22 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $59.68 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $51.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.31 | 2019-2024 | |
| Vbi Vaccine (Delaware) INC. | $45.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $44.25 | 2019-2020 | |
| Boston Scientific Corporation | $36.05 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Depuy Synthes Sales INC. | $35.71 | 2022 | |
| Allergan, INC. | $34.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.57 | 2023 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $29.55 | 2021-2025 | Gardasil 9, Capvaxive |
| Inari Medical, INC. | $24.36 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Corcept Therapeutics | $23.61 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $19.97 | 2025 | Unithroid |
| Supernus Pharmaceuticals, INC. | $18.39 | 2022 | |
| Esperion Therapeutics, INC. | $16.01 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.84 | 2019 | |
| Recor Medical INC | $14.02 | 2024 | Paradise Renal Denervation System |
| Genentech USA, INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oren Zebaida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.